Norgine has signed an agreement to distribute Noventure's Gelsectan in Spain, Portugal and Andorra.
A Class IIa CE marked medical device, Gelsectan is intended to help in treatment of irritable bowel syndrome (IBS) with diarrhoea.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Diarrhoea is one of the symptoms often associated with irritable bowel syndrome.
Gelsectan is available in the form of capsules for oral use.
IBS affects up to 7.8% of the total Iberian population (Spain, Portugal and Andorra).
Every year, over 100,000 new cases are reported and women are twice likely to develop IBS than men.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataNorgine COO Peter Martin said: “We are delighted to be able to offer Gelsectan, a new treatment option to patients who suffer from irritable bowel syndrome (IBS) associated with diarrhoea, a condition which can have a significant impact on quality of life.”
Martin further added: “This recent partnership demonstrates our commitment to sell further specialised innovative products through our well established infrastructure.”
Noventure CEO Luciano Conde said: “Gelsectan is an innovative product that will help to improve the lives of patients across the Iberian Peninsula.
"We are delighted to partner with Norgine, a recognised leader in the treatment of gastrointestinal diseases with a well-established presence in Spain and Portugal.”
Norgine expects to launch Gelsectan in Iberia in the second half of 2017.
Noventure will manufacture Gelsectan.
